-
Views
-
Cite
Cite
Naveen Gara, Marc G. Ghany, What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin, Clinical Infectious Diseases, Volume 56, Issue 11, 1 June 2013, Pages 1629–1636, https://doi.org/10.1093/cid/cit074
- Share Icon Share
Abstract
The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.
Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2013.
Topic:
You do not currently have access to this article.